Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma

Fineline Cube May 21, 2026
Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Company Drug

Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Fineline Cube Apr 1, 2025

China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...

Company Drug

BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer

Fineline Cube Apr 1, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...

Company Drug

Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment

Fineline Cube Apr 1, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...

Company

Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector

Fineline Cube Apr 1, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...

Company Drug

UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis

Fineline Cube Apr 1, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...

Deals Hospital

Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism

Fineline Cube Apr 1, 2025

Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...

Company Drug

AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer

Fineline Cube Apr 1, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...

Medical Device Policy / Regulatory

China Proposes New Measures to Optimize High-End Medical Device Regulation

Fineline Cube Apr 1, 2025

The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...

Company Deals

GE Healthcare Takes Full Ownership of Japan’s Nihon Medi-Physics

Fineline Cube Apr 1, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China

Fineline Cube Apr 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Deals

Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services

Fineline Cube Apr 1, 2025

Chinese companies Nanjing F&S Pharmatech Co., Ltd and Hunan Huize Biopharmaceutical Technology Co., Ltd, a...

Company Drug

Huapont Life Sciences Gains NMPA Approval for Generic Daivobet

Fineline Cube Apr 1, 2025

China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...

Company Deals

Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO

Fineline Cube Apr 1, 2025

China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing...

Company Drug

Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study

Fineline Cube Apr 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...

Company Deals

Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights

Fineline Cube Apr 1, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA...

Company Deals

Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong

Fineline Cube Mar 31, 2025

China-based Chia Tai Tianqing Pharmaceutical has entered into a Named Patient Program (NPP) collaboration with...

Company Drug

Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma

Fineline Cube Mar 31, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...

Posts pagination

1 … 188 189 190 … 669

Recent updates

  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Company Medical Device

Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.